Investment Rating - The report assigns a positive investment rating to JD Health, indicating strong performance and growth potential [4]. Core Insights - JD Health's performance in the second half of 2025 significantly exceeded expectations, with revenue growing by 28% year-on-year to 38.2 billion yuan and adjusted EBITDA increasing by 88% to 1.9 billion yuan [4]. - The company is expected to maintain revenue momentum into 2026, primarily driven by prescription drugs, with adjusted net profit growth projected to remain in the low single digits due to increased investments in O2O, offline pharmacies, and AI [4]. Summary by Sections Revenue Growth - Direct sales revenue increased by 28% year-on-year to 38.2 billion yuan in the second half of 2025, with pharmaceutical sales growing by 30% and nutritional products by 20% [5]. - The number of active users rose to 218 million, a 19% increase year-on-year, representing about 30% of JD's active buyers [5]. Platform and Advertising Revenue - Revenue from platforms, digital marketing, and other services grew by 34% year-on-year to 6.6 billion yuan, driven by increased digital marketing service fees and a rise in the number of advertisers [6]. Profitability - Adjusted EBITDA surged by 88% year-on-year, with a profit margin increase of 1.6 percentage points to 5% due to operational optimization and advertising growth [7]. - Adjusted net profit grew by 38% year-on-year, with a profit margin of 7.7%, reflecting a 0.6 percentage point increase [7]. Catalysts - Support from JD Group's traffic and revenue sharing from advertising, along with favorable policies in the internet and healthcare sectors, are seen as key catalysts for growth [8].

Investment Rating - The report maintains a positive outlook on JD Health, indicating strong sales growth and a favorable investment environment [5][7]. Core Insights - JD Health is expected to maintain robust growth momentum in the second half of 2025, with revenue projected to increase year-on-year, driven by strong performance during the "Double 11" shopping festival and a surge in flu cases in December [5]. - The sales of pharmaceuticals and health products are particularly strong, with adjusted EBITDA expected to double due to margin expansion and operational leverage, offsetting investments in offline stores [5]. - The report highlights that JD Health's direct sales are anticipated to grow year-on-year in the second half of 2025, primarily driven by increased sales of pharmaceuticals and health products during the "Double 11" period [5][6]. Summary by Sections Company Overview - JD Health operates an online retail pharmacy business through self-operated and platform models, focusing on three core categories: pharmaceuticals (including prescription and OTC), health products, and medical devices [10]. Revenue Breakdown - Pharmaceuticals and health products account for 85.3% of revenue, while platform services, advertising, and other sources contribute 14.7% [11]. Market Position - As of February 4, 2026, JD Health's stock price is HKD 60.95, with a market capitalization of USD 26.24 billion and a consensus target price of HKD 76.85 [13].